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PreviewsP2Y2-deficient mice. Although tissue-
specific conditional deletion studies were
not done, radiation chimeras confirmed
that Munc 13-4 is required in circulating
cells and P2Y2 in non-hematopoietic cells
for these effects. These elegant studies
support a molecularly straightforward
model in which activated platelets associ-
ated with CTCs release ATP, which then
acts on endothelial P2Y2 receptors to
reduce endothelial barrier function and
facilitate tumor cell movement out of the
blood (Figure 1).
One of the most exciting aspects of this
study is that it provides ‘‘actionable intelli-
gence’’ in the form of a set of molecular
targets that could potentially be used to
tighten tissue border security in patients
with cancer. While wholesale blockade of
platelet activation and/or adhesion might
reduce tumor metastasis, it would also
increase the risk of bleeding. The study
by Schumacher et al. (2013) suggests
that the P2Y2 receptor might provide a
means of attacking platelet-promoted
metastasis without disabling normal
platelet hemostatic function. P2Y2 recep-
tors have diverse roles in vivo in many
cell types, but the knockout mice are
relatively healthy, and the related P2Y12purinergic receptor is the target of a num-
ber of successful drugs. These character-
istics identify P2Y2 as an attractive drug
target to block tumor metastasis, but
going forward, it will be important to
determine whether the current findings
apply solely to implantable melanoma
and lung carcinoma cell lines or whether
Munc 13-4/P2Y2 inhibition also works
more generally in genetically engineered
models.
A larger question, not addressed by this
study, is what patient population would
benefitmost fromanti-metastatic therapy?
If a tumor is detected prior to metastasis,
then surgical removal of the tumor would
be a preferable and more definitive way
of preventing spread. However, if metas-
tasis has already occurred, even at the
microscopic level, how will reducing
further tumor cell extravasation at that
point lead to an improved outcome? As
with any issue of border control, there will
be debate concerning the best approach.
But before even considering such ques-
tions, it is necessary to know what makes
borders porous and what can be done to
plug the holes; the work of Schumacher
et al. (2013) provides an important new
piece of that basic knowledge.Cancer CREFERENCES
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Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and
clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies
is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive
biomarkers and therapeutic targets for ADT resistance.The mainstay of therapy for metastatic
prostate cancer for more than 70 years
has been systemic androgen ablation,
which was aimed at suppressingandrogen receptor (AR)-mediated sig-
naling as a growth and survival pathway
for prostate cancer cells (Huggins and
Hodges, 1941). The discovery that ARsignaling remains active in castration-
resistant prostate cancers (CRPCs)
(Chen et al., 2004) led to the introduction
of novel antiandrogen therapies, namelyell 24, July 8, 2013 ª2013 Elsevier Inc. 11
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Previewsabiraterone and enzalutamide. The
sustained ADT leads to a variable
initial response because of the genetic
heterogeneity of this disease. Sadly, this
initial response is almost invariably
followed by disease progression. Unfor-
tunately, there are no reliable biomarkers
to predict a response to ADT. The discov-
ery of novel targets and biomarkers for
personalized therapy for CRPC remains
a critical need.
Current concepts and models have
focused largely on persistent AR signaling
as the driving event in the development of
ADT resistance. Specific mechanisms
that override AR signaling and derepress
gene activities inhibited by AR signaling
have been defined (Cai et al., 2011). How-
ever, important fundamental genetic and
biologic pathways including genetic
predisposition, apoptotic signaling, and
proliferative signaling remain fertile
ground for understanding and improving
upon ADT. The use of genetically engi-
neered mouse models (GEMMs) provides
unique opportunities in this regard.
In a recent report, Lunardi et al. (2013)
analyzed the molecular determinants of
androgen dependence of prostate can-
cers that developed in GEMMs with pros-
tate-specific deletion of Pten alone (Pbsn-
cre4;Ptenfl/fl) and in combination with
deletion of Zbtb7a (Pbsn-cre4;Ptenfl/fl;
Zbtb7afl/fl) or Trp53 (Pbsn-cre4;Ptenfl/fl;
Trp53fl/fl). They showed that the loss of
either Zbtb7a or Trp53 confers an initial
resistance to ADT manifested as
increased proliferation, decreased apo-
ptosis, and sustained growth upon
castration. AR was localized mainly in
the cytoplasm one month after castration
in all genotypes. However, tumors with
inactivation of either of the two tumor sup-
pressor genes demonstrated significantly
increased nuclear AR localization, sug-
gesting that the deletion of these two
genes leads to earlier reactivation of AR
signaling than in tumors with functional
alleles.
According to data generated by immu-
nohistochemical staining analysis of
tissue microarrays, which included pros-
tatectomy samples from patients who
had been treated with ADT, and from
genomic hybridization analysis of meta-
static prostate cancer, which included
CRPC (Taylor et al., 2010), the loss of
ZBTB7A was associated with poor
response to ADT, and the loss of both12 Cancer Cell 24, July 8, 2013 ª2013 ElseviZBTB7A and TP53 was frequent in
metastatic CRPC. Interestingly, the loss
of ZBTB7A was significantly associated
with PTEN loss in metastatic CRPC,
suggesting that the concomitant loss of
these genes may be a better predictor of
progression upon androgen deprivation
than PTEN deletion alone.
Comparative analysis of gene expres-
sion profiles of mouse prostate speci-
mens from Pbsn-cre4;Ptenfl/fl with those
from Pbsn-cre4;Ptenfl/fl; Zbtb7afl/fl mice
revealed downregulation of the proapo-
ptotic gene Xaf1, a p53 target gene
that antagonizes the anticaspase activity
of XIAP (Liston et al., 2001), and upregu-
lation of Srd5a1, which catalyzes the
production of dihydrotestosterone by-
passing testosterone (Chang et al., 2011)
in mouse prostates with Pten and Zbtb7a
deletion compared with Pten deletion
alone (Wang et al., 2013). Notably, Xaf1
and the Srd5a1 were found to be down-
regulated and upregulated, respectively,
in prostate cancers with double gene
inactivation compared to tumors with
Pten deletion alone one month after
castration. In addition, when Pten null
tumors presented evidence of resistance
to ADT, expression of Xaf1 was reduced
and Srd5a1 expression increased, further
indicating that this gene expression
signature reflects CRPC. Mechanistically,
the reduced expression of Xaf1 may
explain the lack of apoptotic induction
and proliferation arrest in CRPCs; the up-
regulation of Srd5a1 and the subsequent
increase in dihydrotestosterone levels
may explain the early reactivation of AR
signaling in these tumors. Consistent
with these data, XAF1 downregulation
and XIAP and SRD5A1 upregulation
were found to be associated with a high
Gleason score, recurrence, and metas-
tasis in human samples.
These p53- and ZBTB7A-regulated
biologic and genetic activities led Lunardi
et al. (2013) to hypothesize that the inhi-
bition of XIAP and SRD5A1 sensitizes
prostate cancer cells to AR inhibition.
Indeed, embelin, a XIAP inhibitor, sig-
nificantly increased the apoptotic effects
of ADT and radiation therapy on AR-
positive and AR-negative human prostate
cancer cells in vitro, respectively. More-
over, treatment of Pbsn-cre4;Ptenfl/fl;
Zbtb7afl/fl or Pbsn-cre4;Ptenfl/fl; Trp53fl/fl
mice with bicalutamide together with
embelin significantly enhanced theer Inc.therapeutic effects. Further, the addition
of dutasteride, a SRD5A1 inhibitor, to the
above-mentioned combination therapy
inhibited growth more effectively than
with bicalutamide and embelin in human
prostate cancer cell lines and GEMMs.
On the basis of these results, the inves-
tigators suggested that inactivation of
ZBTB7A and TP53, potentially through
XAF1-mediated inhibition of apoptosis
and SRD5A1-mediated dihydrotestoster-
one production, may provide survival
benefit to prostate cancer cells following
ADT and promote the CRPC phenotype.
Knowledge of these genetic pathways
may translate into reliable markers for
the detection of this type of disease and
also beneficial therapeutic targets.
These new findings show that directly
addressing the biologic pathways that
are affected by ADT— i.e., apoptosis
and proliferation within the context
of genetic predisposition by using
GEMMs—can result in clear, clinically
relevant advances in this important area
of prostate cancer research.
The development of resistance to anti-
cancer therapies, through selection of
cancer cells harboring genetic alterations
including deletions, is a fundamental
challenge in medical oncology. Sustained
targeting of AR signaling by ADT activates
and derepresses multiple signaling
networks such as PI3K/Akt (Carver
et al., 2011), promoting dedifferentiation
and enhancing tumor aggressiveness
and resistance to hormonal manipulation.
Identification of specific genetic alter-
ations that contribute to the development
of resistance to ADT may enable the
prediction of initial resistance and direct
disease management that is focused
on novel therapeutic targets. By using
GEMMs, Lunardi et al. (2013) showed
that the downregulation of XAF1 and up-
regulation of XIAP and SRD5A1 predicted
a poor response to ADT and suggested
that the addition of embelin and dutaster-
ide will improve the response. It would be
interesting to evaluate whether genetic
alterations other than the TP53 and
ZBTB7A deletions can generate this
expression profile and whether tumors
with initial or acquired resistance related
to this signature will respond to these
novel agents (Figure 1).
The Pten prostate-specific knockout
model has been described in multiple
reports, because PTEN inactivation has
Figure 1. The Genetic Profile of Prostate Cancers Predicts Response to ADT and Guides
Therapeutic Decisions
Prostate cancers with genetic alterations resulting from PTEN deletion will present initial sensitivity to ADT
translated to an early tumor regression, but the acquisition of oncogenic events and alterations will lead to
an acquired resistance to ADT and cancer relapse. These tumors demonstrate XAF1 downregulation and
XIAP and SRD5A1 upregulation. Prostate cancers with TP53 and ZBTB7A deletions will present initial
resistance to ADT, whereas the addition of embelin and dutasteride will increase their sensitivity to ADT
and eventually lead to tumor regression. The potential sensitivity to embelin and dutasteride of tumors
with initial resistance related to the XAF1, XIAP, and SRD5A1 genetic profile may provide a second-line
therapy for patients with poor response to ADT.
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Previewsbeen discovered in 15% of primary pros-
tate tumors and in up to 60% of metasta-
tic disease, whereas genetic alterations
of the PI3K signaling occur in 100% of
metastatic prostate cancers (Taylor
et al., 2010). The well-established respon-
siveness of the Pten-deleted tumors to
castration (Wang et al., 2003) along with
the results of early clinical trials evaluating
the combination therapies targeting AR
signaling and PI3K/Akt suggest that the
PTEN deletion is a frequent event during
prostate cancer progression but is notsufficient to create the phenotype of
CRPC. Thus, coclinical GEMMs based
on prostate-specific Pten deletion that
mimic the course of prostate adenocarci-
noma provide a very efficient and flexible
platform for evaluating additional onco-
genic events and alterations contributing
to the development of lethal CRPC.
These results can be translated to the
clinical setting and validated by pre-
existing expression profile data sets.
This approach can set the stage for
the identification of reliable predictiveCancer Cmarkers to guide clinical decisions and
the discovery of effective combina-
tion therapies that will hopefully result
in substantially increased survival for
patients with currently incurable metas-
tatic CRPC.
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